单侧弥散性亚急性视神经视网膜炎患者口服阿苯达唑治疗的临床特点及疗效

• 作 者: Souza E.C. Casella A.M.B. Nakashima Y. Monteiro M.L.R. 陈立军
• 机 构: Av. Angélica 1757 conj. 51 CEP 01227-200 So Paulo Brazil Dr,
• 出 处: 世界核心医学期刊文摘.眼科学分册
• 发表日期: 2006年01期
• 关键词: 视神经视网膜炎 阿苯达唑 蠕虫 干预性 剂量 视力 眼内炎 变异 病例

PURPOSE: To investigate the clinical features,visual function outcomes, and adverse events in patients with diffuse unilateral subacute neuroretinitis (DUSN) treated with high-dose oral albendazole. DESIGN: Interventional case series. METHODS: Twelve Brazilian patients, aged 7 through 36 years, with active DUSN in the early or late clinical stage, were recruited for this study between 1999 and 2001. A small variantmotile worm was found in 4 (33.3% ) of these cases. All patients were treated exclusively with high-dose oral albendazole (400 mg/d) for 30 days. RESULTS: Improvement of visual acuity, visual field, and active ocular in flammatory signs was observed in all patients after 4 weeks of treatment (median follow-up: 3 years). Also, during the first weeks of treatment, evidence of worm inactivation was documented for the four patients with visible worms.No adverse drug side effects were observed in any of our cases during follow-up. CONCLUSION: High-dose oral albendazole seems to be safe and beneficial for patients with DUSN.

PURPOSE: To investigate the clinical features, visual function outcomes, and adverse events in patients with diffuse unilateral subacute neuroretinitis (DUSN) treated with high-dose oral albendazole. METHODS: Twelve Brazilian patients, aged 7 through 36 years , with active DUSN in the early or late clinical stage, were recruited for this study between 1999 and 2001. A small variant worm worm found in 4 (33.3%) of these cases. All patients were treated exclusively with high-dose oral albendazole 400 mg / d for 30 days. RESULTS: Improvement of visual acuity, visual field, and active ocular in flammatory signs was observed in all patients after 4 weeks of treatment (median follow-up: 3 years). Also, during the first weeks of treatment, evidence of worm inactivation was documented for the four patients with visible worms. No adverse drug side effects were observed in any of our cases during follow-up. CONCLUSION: High-dose oral albendazole seems to be safe and beneficial for patients with DUSN.